Rising India Inc (OTCMKTS:RSII) is a new rising star from the OTC, but the catalyst is cannabis news coming out of Ohio! The ten-day volume for RSII has been very impressive clocking in at 28.31M. As mentioned above, the ramp up in interest and volume is due to the company nearing completion of their medical marijuana facility in Ohio.
RSII is seeing a one-week jump of 177% in price. Investors also seem excited by the company’s oral pill, Cannophen, that allows for THC and CBD oil dosing. The pill is intended for non-smokers or for those who need CBD oil benefits but cannot ingest a product. The CEO of RSII adds, “There has never been any proper way to dose with the above-said methods. We have developed Cannophen™ using the strictest quality and control standards and methods set forth in the pharmacy compounding industry using experienced chemists and veteran pharmacists.”
Rising India Inc (OTCMKTS:RSII) bills itself as a new and emerging player in the cannabis patch.
Operating as Rising Biosciences, Inc.is a research and development company focusing on oral and topical cannabis and non-cannabis based pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry.
The company had been trumpeting itself as “a publicly traded United States company that seeks to accelerate growth through possible joint ventures, mergers, and/or new acquisitions pertaining to development and deployment of media.” The company actually incorporated on April 29, 1998, as a media holding company – an animation company working to develop and market various international media projects. The Company has announced acquisitions, joint-ventures and/or mergers with operating film and media operations pertaining to support and transactional businesses within the film and media industry.
Recently, as noted above the company entered into the cannabis industry wholly and completely via a reverse merger with Rising BioSciences, Inc., which is now the company in charge of the RSII ticker as far as we can determine.
In addition, the company’s website notes their continued interest in developing independent living, assisted living and memory center communities. However, we suspect that this is not an updated concept outline for Rising India in any regard.
Find out when $RSII stock reaches critical levels. Subscribe to FinanceRegistrar.com Right Now by entering your Email in the box below.
In addition, the company is testing a cannabis painkiller. RSII is approaching this space with a medical mindset. They intend on being fully functional in their medical marijuana lab, which will emphasis on research, development, manufacturing and licensing of innovative offerings in the Cannabis space committed to serving patients with the best standards.
The COO of RSII expressed that they have also had remarkable feedback from those that obtained study tasters of the Clinical Strength Scar Peptide Serum and they now move into the subsequent phase of production. The company together with PAO Group Inc. is assisting lower the grip of opioids on America by focusing its efforts on the responsible cannabis use.
At this time, holding a market cap of $6.49M, RSII is looking to enter this space as a niche play, but CBD oils have always been one of the more lucrative aspects to cannabis. As we have stated previously, cannabis is just starting to get going and more institutional investors are coming into the market. RSII could be a nice medical play in your cannabis portfolio. We will be writing more updates as information comes out on their facility in Ohio. Sign-up for continuing coverage on shares of $RSII stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $RSII, either long or short, and we have not been compensated for this article.